

To the Press:

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

1 November 2010

Exiqon's miRCURY LNA™ microRNA Array product line selected as preferred platform by multinational company. Data in support of Exiqon's detection platform were presented at the microRNA Europe Conference held in Cambridge, United Kingdom

Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression analysis products, today announced that dr. Alain Sewer, Phillip Morris International, R&D, Neuchatel, Switzerland, has presented data from a comprehensive validation study of the miRCURY LNA™ microRNA Array product line.

Dr. Sewer's data demonstrate that the LNA™-enhanced capture probes secure very sensitive and specific detection of microRNAs in complex samples. The study concludes that Exiqon's miRCURY LNA™ microRNA Array platform outperforms similar products provided by a main competitor.

Exiqon's microRNA arrays feature Tm-normalized, LNA™-enhanced capture probes, designed by advanced bioinformatics algorithms for excellent specificity and sensitivity for all microRNAs in more than 100 different species.

The miRCURY LNA™ microRNA Array product line includes the miRCURY LNA™ microRNA Arrays, miRCURY LNA™ microRNA Power Labeling Kits and the miRCURY LNA™ microRNA Array Analysis Software. The products are provided with protocols for a number of different instrument platforms.

"We are always pleased when a major international customer publishes the conclusions from their internal validation studies. In this publication, it is demonstrated that Exiqon's products are superior in terms of sensitivity and specificity which represent the most important values for our customers", said Henrik M. Pfundheller, VP Sales & Marketing at Exiqon.

About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading



providers of miRNA research products for miRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on miRNA as biological markers (Exiqon Pharma Services). Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.

Additional information

Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)

Henrik M. Pfundheller, VP Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090 2106)

